This page shows the latest Bispecific antibodies news and features for those working in and with pharma, biotech and healthcare.
The company will be introducing its next wave of IO therapies, sharing the first clinical results for MEDI5752 – a novel bispecific antibody, which simultaneously targets immune checkpoint proteins in solid tumours. ... Bispecific antibodies are a
Amgen already has its own antibody technology – known as BiTE – which enables the identification and development of bispecific T cell engager antibodies. ... TNB-585 is a bispecific T cell-engager being evaluated for the treatment of metastatic
The companies will evaluate Genmab’s antibodies and bispecific antibody engineering technologies alongside Bolt’s immune-stimulating antibody conjugate (ISAC) technology platform. ... We are delighted to be collaborating with the Genmab team and to
Pfizer has paused enrolment for a phase 2 trial evaluating its anti-BCMA bispecific antibody elranatamab, following three cases of peripheral neuropathy in an ongoing phase 1 study. ... development. “Bispecific antibodies hold promise as the next
Bispecific antibody fails in non-small cell lung cancer trial. Bintrafusp alfa – the novel immunotherapy at the centre of a major alliance between GlaxoSmithKline (GSK) and Merck KGaA – has failed in ... Bintrafusp alfa is part of a new wave of
Eli Lilly has entered a research collaboration agreement with Dutch biotech Merus to develop CD3-engaging bispecific antibodies for the treatment of cancer. ... products. "CD3-engaging bispecific antibodies are rapidly becoming one of the most
More from news
Approximately 5 fully matching, plus 23 partially matching documents found.
It hopes to break into the big league with the launch of its own proprietary product by 2025 in addition to a string of collaborations based on its novel antibodies. ... In addition to traditional antibodies, the pipeline also includes antibody drug
511. BioInvent (Sweden). Pfizer (US). Research collaboration. Development of immuno-regulatory antibodies targeting tumour-associated myeloid cells. ... Technology. Merus. Incyte. $3, 000m. $120m plus $80m equity. Bispecific antibodies.
In return, Zymeworks is licensing immuno-oncology antibodies from Daiichi Sankyo, in exchange for royalties on sales. ... 624. EngMab / Celgene. Acquisition corporate. T cell bispecific antibodies that bind simultaneously to a tumour antigen and the T
2 T-cell engaging XmAb bispecific antibodies: XmAb14045 for AML and XmAb13676 for B-cell malignancies (preclinical) and other rights. ... licence. 125. EpimAb Biotherapeutics/ Innovent Biologics. Fabs-In-Tandem immunoglobulin platform to develop multiple
The collaboration provides GSK with a platform technology to develop bispecific antibodies. ... 125 . Enumeral (US). Pieris (DE). License &option to further programme. Discovery state 388D4 programme of PD1 Monoclonal Antibodies immunotherapies.
More from intelligence
Approximately 0 fully matching, plus 10 partially matching documents found.
Dr Kayitalire’s background will be of benefit to F-star, as it looks to advance its bispecific antibody pipeline in oncology. ... pipeline. As we saw at the recent ASCO meeting, bispecific antibodies are leading a paradigm shift in cancer care and the
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...